US 11,883,087 B2
Selective modulation of renal nerves
Stefan Tunev, Santa Rosa, CA (US); and Julie Trudel, Santa Rosa, CA (US)
Assigned to Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed by Medtronic Ireland Manufacturing Unlimited Company, Dublin (IE)
Filed on Sep. 30, 2022, as Appl. No. 17/937,289.
Application 17/937,289 is a continuation of application No. 16/409,442, filed on May 10, 2019, granted, now 11,457,968.
Application 16/409,442 is a continuation of application No. 14/379,834, granted, now 10,342,592, issued on Jul. 9, 2019, previously published as PCT/US2013/029526, filed on Mar. 7, 2013.
Claims priority of provisional application 61/608,022, filed on Mar. 7, 2012.
Prior Publication US 2023/0024234 A1, Jan. 26, 2023
Int. Cl. A61B 18/14 (2006.01); A61B 18/04 (2006.01); A61N 1/05 (2006.01); A61N 1/36 (2006.01); A61B 18/02 (2006.01); A61B 18/18 (2006.01); A61M 25/00 (2006.01); A61N 1/32 (2006.01); A61N 7/00 (2006.01); A61B 18/00 (2006.01)
CPC A61B 18/04 (2013.01) [A61B 18/02 (2013.01); A61B 18/1492 (2013.01); A61B 18/1815 (2013.01); A61M 25/0084 (2013.01); A61N 1/0551 (2013.01); A61N 1/327 (2013.01); A61N 1/3605 (2013.01); A61N 7/00 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/046 (2013.01); A61M 2025/0089 (2013.01); A61M 2202/048 (2013.01); A61M 2202/049 (2013.01); A61N 2007/003 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method for treating a human patient with diagnosed systemic sympathetic overactivity, the method comprising:
neuromodulating afferent and efferent renal nerves in the human patient,
wherein neuromodulating afferent and efferent renal nerves includes selectively neuromodulating efferent renal nerves such that a greater percentage of efferent renal nerves are modulated relative to a percentage of modulated afferent renal nerves, and
wherein selectively neuromodulating the efferent renal nerves in the human patient improves a measurable physiological parameter corresponding to the systemic sympathetic overactivity of the human patient.